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2. ABBREVIATIONS 
NO nitric oxide 
HMG-CoA 3 -hydroxy-3 -methyl-glutaryl-Co A 
NOS NO synthase 
MMP matrix metalloproteinase 
PKC protein kinase C 
ROS reactive oxygen species 
cGMP cyclic guanosine 3': 5' -monophosphate 
TIMP tissue inhibitor of metalloproteinases 
ONOO" peroxynitrite 
TTC triphenyltetrazolium-chloride 
LDH lactate dehydrogenase 
DETC diethyl-dithio-carbamate 
NBT nitro blue tetrazolium 
QRT-PCR quantitative polymerase chain reaction 
SSC saline sodium citrate 
ANOVA one way analysis of variance 
EST expressed sequence tag 
START domain steroidogenic acute regulatory protein-related lipid transfer domain 
CEACAM9 carcinoembryonic antigen-related cell adhesion molecule 9 
CLIC chloride intracellular channel 
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3. SUMMARY 
Cardiac stress adaptation, i.e. preconditioning, is deteriorated in hyperlipidemia, but the 
underlying mechanisms are still undiscovered. Bioavailability of a major effector of 
preconditioning, nitric oxide (NO), is decreased in hyperlipidemia, however, inhibition of 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, a key enzyme of the mevalonate 
pathway (cholesterol synthesis), increases the endothelial NO synthase (eNOS) mRNA level. 
Release and activation of matrix metalloproteinases (MMPs) contribute to myocardial injury 
after ischemia/reperfusion, but their role in preconditioning and in the loss of preconditioning in 
hyperlipidemia is not known. Therefore, here we have studied the role of dietary and 
pharmacological inhibition of the mevalonate pathway on cardiac NO metabolism in normal and 
hyperlipidemic animals; and we have looked at the activation and release of MMPs in 
preconditioning. Moreover, since hyperlipidemia-induced gene expression changes of the rat 
heart have not been investigated to date, we performed a cDNA microarray study as well. Rats 
were fed with 2% cholesterol-enriched or normal diet for 9 weeks. Normal and hyperlipidemic 
animals were treated with farnesol, a major metabolite of the mevalonate pathway, or with 
lovastatin, a HMG-CoA reductase inhibitor. In separate experiments, isolated hearts of normal 
and hyperlipidemic rats were subjected to a preconditioning protocol (3x5 min ischemia and 
reperfusion) followed by 30 min ischemia and 2 h reperfusion, or a time matched non-
preconditioning protocol. We have found that hyperlipidemia decreased cardiac NO level, 
however, dietary or pharmacological inhibition of the mevalonate pathway did not influence 
cardiac NO metabolism. Neither hyperlipidemia, nor farnesol, or lovastatin affected cardiac 
NOS activity or eNOS protein level. Preconditioning decreased infarct size and deteriorated 
release and activation of MMP-2 in normal but not in hyperlipidemic animals. A reduction of 
infarct size in non-preconditioned hearts from both control and hyperlipidemic group was 
produced by the MMP inhibitor ilomastat. DNA microarray analysis of 3200 genes revealed that 
dietary hyperlipidemia up-regulated cardiac expression of 26 genes, while 25 showed down-
regulation. Taken together, hyperlipidemia blocks preconditioning-induced cardioprotection, in 
which enhanced post-ischemic myocardial activation and release of MMP-2 play a significant 
role. Furthermore, we conclude that pharmacological inhibition of MMPs is a valid option to 
mimic the cardioprotective effect of preconditioning in both normal and hyperlipidemic animals. 
Although some genes, expression of which is altered by hyperlipidemia, have been suspected to 
be related to cardiovascular diseases, none of them have been previously shown to be involved 
in cardiac effects of the hyperlipidemia. Therefore, our present findings may open new 
directions in the research of the cardiac effects of hyperlipidemia. 
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4. INTRODUCTION 
4.1. Ischemic preconditioning 
Ischemic heart diseases are the leading cause of death in developed countries, e.g. they were 
responsible for the 23% of deaths in Hungary in 2003 [1], Moreover, prevalence of factors that 
increase the risk of ischemic heart diseases such as obesity, smoking and diabetes is also a huge 
problem in these societies. Therefore, investigation of cardioprotective mechanisms is of great 
importance. 
Ischemic preconditioning is a well-described adaptive response in which brief exposure to 
ischemia markedly enhances the ability of the heart to withstand a subsequent ischemic injury 
(see for reviews) [2, 3], A great number of mechanisms have been shown to play a role in 
preconditioning. For example, activation of protein kinase C (PKC) isoforms [4], opening of 
sarcolemmal and mitochondrial ATP sensitive potassium channels [5, 6], and prostaglandin-
related pathways [7] is involved in the cardioprotective mechanism of preconditioning. 
Although preconditioning confers a remarkable cardioprotection in a variety of species 
including humans, it seems that its effectiveness is attenuated in several disease states such as 
hyperlipidemia, diabetes, heart failure, nitrate tolerance etc. (see for reviews) [8, 9], However, 
most studies show that hyperlipidemia inhibits the cardioprotective effect of preconditioning 
(when looking at end-points such as ST-segment elevation or cardiac function), but there is a 
controversy whether the most relevant factor of the preconditioning the infarct-size limiting 
effect is lost in hyperlipidemia (see for review) [9]. The discrepancies can be attributed to the 
substantial differences in hyperlipidemia models (species, duration of hyperlipidemic diet, 
presence of significant coronary sclerosis). Therefore, we have chosen Wistar rats to study the 
direct cardiac effects of dietary cholesterol, as this species shows moderate increase in serum 
cholesterol level due to a high-cholesterol diet without substantial development of 
atherosclerosis [10-12], 
Mechanisms by which hyperlipidemia abrogates the protective effect of preconditioning are 
not exactly known, however, several mechanisms have been proposed. A variety of mechanisms, 
i.e. inhibition of heat shock response [13], and expression of oxidized low-density lipoprotein 
receptors which induces apoptosis [14, 15] have been shown to play a role in the cardiac effects 
of hyperlipidemia. Thus, it appears that the hyperlipidemia-induced loss of preconditioning is 
based on a direct effect of hyperlipidemia on the myocardium rather than an indirect effect 
through coronary sclerosis [10, 16], 
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4.2. NO and hyperlipidemia 
NO plays an important role in the regulation of coronary circulation, contractile function, 
and ischemic adaptation of the heart [17] by modulation of cardiac muscle contractile function, 
and by inhibiting oxygen consumption [18, 19]. In physiological conditions, NO is generated by 
isoforms of NOS which catalyzes the conversion of L-arginine to NO and L-citrulline (see for 
review) [20]. NOS belongs to a family of P-450 cytochrome oxidoreductase enzymes. In normal 
hearts, NO is synthesized by Ca2+-dependent NOS isoforms in cardiac myocytes, vascular, and 
endocardial endothelium (eNOS) and in specific cardiac neurons (nNOS). Under pathological 
conditions (e.g. during inflammation or bacterial infection), temporary high level of NO is 
produced after the expression of a Ca2+-independent, inducible NOS (iNOS). Bioavailability of 
NO is decreased in several diseases due to excess of reactive oxygen species (ROS) possibly 
produced by malfunctioning oxidative enzymes such as NAD(P)H oxidases or xanthine 
oxidoreductase [21, 22]. Thus, formation of NO-related ROS e.g. peroxynitrite (ONOO") could 
increase, which lead to deterioration of several mechanisms and oxidative modification of 
numerous macromolecules (see for review) [23]. 
Increasing number of evidence accumulated in recent years showing that high-cholesterol 
diet impairs NO - cyclic guanosine 3':5'-monophosphate (cGMP) signaling in both endothelial 
and non-endothelial cells [10, 24, 25]. We have previously shown that cardiac NO level is 
significantly decreased in rats with experimental hyperlipidemia [10]. In contrast to the 
aforementioned findings, inhibition of HMG-CoA reductase, the key enzyme of the endogen 
cholesterol synthesis, by statins has been shown to increase mRNA level of eNOS in human 
endothelial cells [26, 27]. It is not known, however, if dietary, or pharmacological inhibition of 
HMG-CoA reductase affects NO synthesis significantly in the heart tissue, and if the mevalonate 
pathway plays a role in the regulation of cardiac NO metabolism. 
4.3. Preconditioning and MMPs 
We have previously reported that ONOO", a highly reactive product of NO and superoxide, 
is involved in preconditioning [28], and that hyperlipidemia leads to enhanced formation of 
ONOO" [29]. A significant cellular target of ONOO* is oxidative activation of the MMPs [30]. 
MMPs are a large family of over 20 Zn2+ -containing endopeptidases synthesized as 
proenzymes by various tissues. MMPs are subdivided into 5 groups, namely matrilysins, 
collagenases, stromelysins, membrane-type MMPs, and gelatinases. Each subfamily has unique 
domain sequence and, therefore, substrate specificity. MMPs are responsible for long-term 
degradation and remodeling of the extracellular matrix, and play a significant role in numerous 
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physiological and pathological processes such as angiogenesis [31], and remodeling after acute 
myocardial infarction [32], Activity of MMPs is additionally regulated by their endogen 
inhibitors, tissue inhibitors of metalloproteinases (TIMPs). MMP proenzymes are usually 
activated via limited proteolysis by the cleavage of an autoinhibitory pro-peptide domain. 
However, it has been demonstrated that oxidizing agents can activate MMPs via a non-
proteolytic oxidative mechanism by oxidizing the sulphydryl bond between a cystein residue of 
the pro-peptide domain and the Zn2+ catalytic center, resulting in fully active proenzymes 
without a change in molecular weight (Fig. 1) [30], 
Figure 1. Activation of MMPs. 
Recently, it has been demonstrated that MMPs play a role not only in long-term extracellular 
matrix remodeling, but also in acute regulation of cardiac function. For example, MMP-7 
promotes vasoconstriction in rat mesenteric arteries [33] and ischemia-induced activation and 
release of gelatinase-A (MMP-2) is a major effector of acute mechanical dysfunction after 
ischemia-reperfusion in rat hearts [34-36]. Furthermore, signaling pathways involved in the 
mechanism of ischemic preconditioning influence the expression or activation of MMPs. For 
example, activation of PKC-lj and 6 subtypes increases expression of MMP-2 in rat cardiac 
fibroblast culture [37], Phosphatidylinositol 3-kinase-dependent upregulation of membrane-type 
1-MMP expression modulates MMP-2 activity in injured pig coronary arteries [38], However, it 
is not known if MMPs and their endogenous inhibitors, the TIMPs, play a role in 
cardioprotection produced by preconditioning. Furthermore it is unknown if inhibition of MMPs 
plays a role in the loss of preconditioning-induced cardioprotection in hyperlipidemia. 
We hypothesized that hyperlipidemia blocks the infarct size limiting effect of 
preconditioning due to the loss of inhibition of MMP activation and release induced by 
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preconditioning. Furthermore, we speculated that an imbalance between MMP activity and 
TIMPs may be involved in this mechanism. 
4.4. Does hyperlipidemia modulate cardiac gene expression? 
Underlying molecular mechanisms of direct effects of cholesterol diet-induced 
hyperlipidemia on the myocardium have been addressed by a few studies, but the exact 
biochemical mechanisms are still a question of debate. We suspected several possible 
mechanisms, such as alteration of NO bioavailability and increased oxidative stress; however, 
traditional biochemical and pharmacological approaches seem to be insufficient so far to explore 
key cellular events in the heart in hyperlipidemia. Recent studies have attempted to identify gene 
activity changes in atherosclerotic plaques in human and animal blood vessel samples [39, 40], 
but gene expression pattern of the heart in response to hyperlipidemia induced by chronic 
cholesterol-enriched diet is not known. Hence, performing cDNA microarray studies on the heart 
may help us identifying new cellular pathways involved in the direct cardiac effects of 
hyperlipidemia induced by dietary cholesterol. 
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5. AIMS 
Aims of our present studies were: 
Study 1: to investigate the effect of the modulation of the mevalonate pathway by dietary 
cholesterol and by the HMG-CoA reductase inhibitor lovastatin on cardiac NO level and NOS 
activities in rat hearts. 
Study 2: to assess the infarct size limiting effect of preconditioning in normal and 
cholesterol-enriched chow-fed rats; to measure activation and release of cardiac MMP-2, and its 
inhibitors, TIMP levels. Furthermore, we studied the possible infarct size limiting effect of 
pharmacological inhibition of MMPs in control chow and cholesterol-enriched chow-fed rats in 
order to prove the link between MMP inhibition and cardioprotection. 
Study 3: to profile the gene expression pattern of the heart associated with hyperlipidemia 
using cDNA microarrays in the hope of identifying new cellular pathways involved in the direct 
cardiac effects of hyperlipidemia induced by dietary cholesterol. 
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6. MATERIALS AND METHODS / 
6.1. Induction of hyperlipidemia 
Eighteen-week old male Wistar rats were fed normal or 2% cholesterol-enriched diet for 9 
f 
weeks. Body weights of the animals after the diet period were\^20-500 g^and there was no 
significant difference between control and cholesterol-fed groups. WiStarrats were chosen for 
the study since they show moderate increase in serum cholesterol level due to high-cholesterol 
diet without substantial atherosclerosis [12]. The 9-week cholesterol-enriched diet increased 
serum cholesterol from 1.45±0.05 to 1.92±0.10 (n=6 in each group, #<0:05)~and~"serum 
triglyceride from 0.52±0.04 to 1.25±0.14 mM (n=6-12,p<0.05). . ' I • | X r V 
6.2. Experimental design 
6.2.1. Study 1: 
Animals on normal or cholesterol-rich diet were treated either with the HMG-CoA reductase 
inhibitor lovastatin (3x5 mgxkg"1 per os for 3 days at the end of diet), or farnesol, a major 
metabolite of the mevalonate pathway (2x2.2 mgxkg"1 i.p., 6 and 1 hours before isolation of 
hearts, n=5-6 in each group). 
Rats were then anesthetized, heparin (500 Uxkg"1 i.v.) was given, and the heart was isolated 
and perfused for 1 min at 37 °C in Langendorff mode with Krebs-Henseleit buffer to wash out 
blood. Ventricular tissue was frozen for further measurements of NOS activities, and NOS 
protein. ^ j 
• 
f 
6.2.2. Study 2: ^ -
At the end,of the diet-period, rats were anesthetized with diethyl ether, heparin (500 Uxkg 
administered, and hearts were isolated and perfused with Krebs-Henseleit buffer in 
Langendorff mode for 15 min at 37 °C. Hearts from cholesterol-fed or control rats were 
subjected to a no-flow ischemia-induced preconditioning protocol (3x5 min ischemia and 5 min 
reperfusion) or a time matched non-preconditioning protocol each followed by test 
ischemia/reperfusion (30 min global normothermic ischemia followed by 120 min reperfusion) 
(Fig. 2). In separate experiments, ventricular tissue was freeze-clamped and crushed at liquid N2 
temperature after the initial 15 min perfusion or at the 5th min of reperfusion for zymography 
and western blot studies. Coronary perfusate samples were collected before preconditioning for 
5 min and during the first 5 min of reperfusion after test ischemia for zymographic analysis and 
for coronary flow measurement (Fig. 2). Heart rate was monitored as previously described [41]. 
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In separate experiments, after determination of a suitable concentration of ilomastat for 
MMP-2 inhibition (see below), hearts from control and cholesterol-fed groups were perfused 
with Krebs-Henseleit buffer containing 0.1 or 0.25 pM MMP-inhibitor ilomastat (GM-6001; 
CHEMICON, Temecula, CA) throughout the perfusion protocol and subjected to test 
ischemia/reperfusion (30 min global normothermic ischemia, followed by 120 min reperfusion) 
without preceding preconditioning (Fig. 2). 
Fig. 1 
ischemic control 
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(Control Pre) 
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Figure 2. Experimental protocol - study 2. 
Control and 2% cholesterol-enriched chow-fed animals were subjected to either 3x5-5 min 
ischemia-reperfusion (Control Pre, Choi Pre), or time-matched aerobic perfusion without 
preconditioning (Control, Choi) followed by 30 min test ischemia and 120 min reperfusion. 
Coronary perfusate was collected before the first preconditioning occlusion and corresponding 
control periods, as well as upon the first 5 min of reperfusion after test ischemia. Infarct size 
measurement was performed at the 120th min of reperfusion. In separate experiments, left 
ventricles were frozen in liquid nitrogen after the initial 15 min perfusion or at the 5th min of 
reperfusion after test ischemia for MMP measurements. Hearts of normal or cholesterol-enriched 
chow-fed animals were subjected to nonpreconditioning protocol in the presence of 0.1 or 0.25 
pM MMP-inhibitor ilomastat (Control+ilo, Chol+ilo) as well. 
6.2.3. Study 3: 
Animals were anesthetized and 500 Uxkg"1 heparin was given. Hearts from normal and 
hyperlipidemic rats (n=8 in each group) were then isolated and perfused in Langendorff mode 
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with Krebs-Henseleit buffer for 5 min. Subsequently, the perfusion was switched to a working 
mode [42,43] to measure cardiac mechanical functional and hemodynamic parameters including 
heart rate, coronary flow, aortic flow, left ventricular developed pressure and its first derivatives 
(+dP/dtmax, -&P/dtmax), and left ventricular end-diastolic pressure as described [44]. Lactate 
dehydrogenase release (LDH) was measured from coronary effluent collected for 5 min at the 
beginning of the perfusion [42]. At the end of the perfusion protocols, ventricles of hearts from 
both groups were cut out, immediately frozen, and powdered with a pestle and mortar in liquid 
nitrogen for RNA preparation. 
6.3. Measurement of cardiac NO by electron spin resonance spectroscopy 
To measure NO level in cardiac tissue directly, in vivo spin-trapping of NO was applied, 
followed by ESR analysis of left ventricular tissue samples as described [42, 43, 45, 46]. The 
spin trap diethyl-dithio-carbamate (DETC, 200 mgxkg"1), 50 mgxkg"1 FeS04 and 200 mgxkg"1 
sodium citrate were slowly administered intravenously into the femoral vein under ether 
anesthesia. DETC dissolved in distilled water was injected separately from FeS04 and sodium 
citrate in 0.5 ml total volume to avoid precipitation of Fe2+(DETC)2. FeS04 and sodium citrate 
were dissolved in distilled water, the pH was set to 7.4 with 1 M NaOH, and brought to 1 ml 
volume before injection. Five minutes after DETC, FeS04, and citrate treatment, hearts were 
isolated and perfused in Langendorff mode for 1 minute to eliminate blood, and approximately 
150 mg tissue samples of the left ventricles were placed into quartz ESR tubes, frozen in liquid 
nitrogen until assayed for ESR spectra of the NO-Fe2+(DETC)2 complex. Fe2+(DETC)2 has high 
affinity for NO while forming NO-Fe (DETQ2. The specific triplet signal of the NO-
Fe2+(DETC)2 
is superimposed on the dominant background spectra of CU2+(DETC)2. The 
detection limit of NO by this ESR method is 0.05 nM [47]. ESR spectra was recorded with a 
Bruker ECS 106 (Rheinstetten, Germany) spectrometer operating at X band with 100 kHz 
modulation frequency at a temperature of 160 K, using 10 mW microwave power to avoid 
saturation. Scans were traced with 2.85 G modulation amplitude, 340 G sweep width, and 3356 
G central field as described [47]. After subtraction of the background signal of Cu2+(DETC)2, 
analysis of NO content was performed with double integration. Values were expressed in 
arbitrary units. 
6.4. Measurement of NOS activities 
NOS activities in cardiac homogenate of frozen ventricular tissue were determined from the 
rate of conversion of L-[14C]arginine to 
L-[14C]citrulline as described [43, 48]. Briefly, 20 pi 
supernatant of freshly homogenized heart sample was incubated in 100 pi reaction solution 
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containing 50 mM KH2P04, adjusted to pH 7.2 with 2N KOH; 1.2 mM MgCl2, 0.24 mM CaCl2, 
50 mM L-valine, 10 pM 6(R,S)-5,6,7,8-tetrahydrobiopterin-2 HCI, 1 mM dithiotreitol, 100 pM 
NADPH, 18 pM L-arginine, 1 mM L-citrulline, 2 pM L-[14C]arginine, in the presence or 
absence of either EGTA (1 mM) or EGTA plus NG-monomethyl-L-arginine (1 mM). After 25 
min incubation at 37 °C, reaction was terminated with the addition of 1ml 50% slurry AG 50W-
X8 activated cation-exchanger resin (Bio-Rad Laboratories, Hercules, CA). Supernatant was 
vortexed thoroughly with Opti Phase HiSafe-3 (0.7:2 v/v, PerkinElmer, Wellesley, MA) in 
scintillation tube, and counted by Tri-Carb 2100TR liquid scintillation counter (PerkinElmer, 
Wellesley, MA) in direct DPM mode. Ca2+-dependent and -independent NOS activities were 
expressed in pmolxmin'xmg"1 protein. 
6.5. Measurement of superoxide production 
To assess if hyperlipidemia leads to increased cardiac superoxide formation, in separate 
experiments, superoxide production in freshly minced ventricles was assessed by lucigenin-
enhanced chemiluminescence in normal and hyperlipidemic control groups [43, 19]. 
Approximately 100 mg of the apex of the heart was placed in 1 ml air-equilibrated Krebs-
Henseleit solution containing 10 mM HEPES-NaOH (pH 7.4) and 5 pM lucigenin [43]. 
Chemiluminescence was measured at room temperature in a liquid scintillation counter using a 
single active photomultiplier positioned in out-of-coincidence mode in the presence or absence 
of the superoxide scavenger nitro blue tetrazolium (NBT, 200 pM). NBT-inhibitable 
chemiluminescence was considered an index of myocardial superoxide generation. 
6.6. Measurement of infarct size 
After test ischemia/reperfusion, 5 ml of 1% triphenyltetrazolium-chloride (TTC) dissolved 
in phosphate buffer (pH 7.4) was slowly injected for 5 min into the aortic root to stain the 
myocardium. TTC-stained hearts were frozen (-20 °C), cut into approximately 3 mm thick slices, 
and scanned between glass plates. TTC-stained red and unstained pale areas of images were 
quantified by planimetry (Adobe Acrobat Professional, Adobe, San Jose, CA). Infarct size was 
represented as a percentage of total heart volume. 
6.7. Measurement of LDH release 
LDH release of hearts was measured using a LDH-P kit (Diagnosticum, Budapest, Hungary) 
from coronary perfusates collected for 5 min upon reperfusion after test ischemia. LDH release 
was expressed as mUxmin"1xg"1wet heart weight. 
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6.8. Zymographic analysis of MMP activity 
To measure myocardial MMP-2 activity and its release into the perfusate, we collected heart 
tissue and coronary perfusate samples 10 min after starting perfusion protocol for 5 min, and for 
5 min after test ischemia (Fig. 2). Gelatinolytic activities of MMPs were examined as previously 
described [34]. Briefly, 8% polyacrylamide gels were copolymerized with 2 mgxml"1 gelatin and 
a constant amount of protein per lane (coronary perfusate, 15 pg; ventricular homogenate, 40 
pg) was loaded. An internal standard (supernatant of phorbol ester activated HT-1080 cells, 
American Type Culture Collection, Manassas, VA) was loaded into each gel to normalize 
activities between gels. Following electrophoresis (150 V, 1.5 h), gels were washed with 2.5% 
Triton X-100 for 3^15 min, and incubated for 24-48 h at 37 °C in incubation buffer (50 mM 
Tris-HCl, 150 mM NaCl, 5 mM CaCl2, and 0.05% NaN3, pH 7.4). Gels were then stained with 
0.05% Coomassie Brilliant Blue (G-250, Sigma, St. Louis, MO) in a mixture of methanohacetic 
acid:water (2.5:1:6.5, v/v) and destained in aqueous mixture of 4% methanol and 8% acetic acid 
(v/v). Since MMP-2 digests its substrate the gelatin in the zymographic gel, gelatinolytic 
activities are detectable as transparent bands against the dark blue background at the appropriate 
molecular weight (75, 72 and 68 kDa). Zymograms were digitally scanned and band intensities 
were quantified using Quantity One software (BioRad Laboratories, Hercules, CA) and 
expressed as a ratio to the internal standard. Band density was expressed as arbitrary unitsxmg"1 
protein to exclude a possible nonspecific release of MMP into the perfusate during ischemia. 
6.9. Selection of ilomastat concentration for appropriate inhibition of 
cardiac MMP-2 activation 
The concentration-response relationship of the MMP-2 inhibitory effect of ilomastat in rat 
heart tissue homogenate was determined in vitro. Hearts (n=3) from control rats were aerobically 
perfused for 15 min to wash out blood, then left ventricles were rapidly frozen, homogenized, 
and zymography was performed as described above. The incubation buffer of zymography 
contained 0, 0.01, 0.1, 0.25, 0.5,1 or 10 pM ilomastat during the first 3 h of the 24 h incubation. 
Three hours incubation in the presence of ilomastat was selected as the perfusion protocol in the 
ex vivo heart was 3 hours in duration. 
6.10. Western blot analyses 
To assess cardiac TIMP-2 and TIMP-4 protein levels, cardiac tissue was frozen 5 min after 
test ischemia. Cardiac eNOS protein was determined from samples frozen after the initial 5 min 
aerobic perfusion. Cardiac tissue was then homogenized and diluted to load 15 pg of total 
protein on 6 or 12% polyacrylamide gel. Electrophoresis (150 V, 1.5 h) and blotting onto 
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nitrocellulose membrane (35 V, 1 h) was performed. Nitrocellulose membranes were then 
blocked overnight in Tris-buffered saline solution containing 0.1% Tween-20 and 5% skimmed 
milk powder. Membranes were then incubated with mouse monoclonal anti-TIMP-2 antibody 
(Calbiochem IM56L, Merck, Darmstadt, Germany), or with rabbit polyclonal anti-TIMP-4 
antibody (Chemicon AB816, CHEMICON, Temecula, CA), or with mouse monoclonal anti-
eNOS antibody (Transduction Laboratories Lexington, KY) for 1.5 h. Rabbit anti-mouse IgG or 
goat anti-rabbit IgG secondary antibodies (P0161 and P0448 respectively, DakoCytomation, 
Glostrup, Denmark) were used for incubation at 37 °C for 2 h, as appropriate. Membranes were 
developed with an enhanced chemiluminescence kit (ECL Plus, Amersham Biosciences, 
Uppsala, Sweden), exposed to X-ray film and scanned. Band density was calculated by 
integrating the area (in pixels*intensity, expressed in arbitrary units). 
6.11. Cardiac nitrotyrosine measurement 
As a marker of baseline cardiac ONOO" formation, we have measured cardiac nitrotyrosine 
level by enzyme-linked immunosorbent assay (Cayman Chemicals, Ann Arbour, MI) from heart 
tissue homogenate of control and cholesterol-fed groups sampled after the initial 15 min 
perfusion (Fig. 2) according to the manufacturer's instructions. Nitrotyrosine content was 
normalized to protein content of cardiac homogenate and expressed as pgxmg"1 protein. 
6.12. Protein assay 
Protein concentrations were measured by the bicinchoninic acid assay (Sigma, St. Louis, 
MO) with bovine serum albumin as a standard. 
6.13. RNA preparation 
Total RNA was purified (25-25 mg tissue from each heart) with NucleoSpin RNA 
purification kit (Macherey-Nagel, Düren, Germany) according to the manufacturer's instructions 
as described [49]. The quantity and quality of RNA from each sample was assessed by gel 
electrophoresis as well as spectrophotometry (NanoDrop spectrophotometer, NanoDrop, USA). 
Two RNA pools were prepared from each group (n=4, randomly selected from each group) and 
used in replica experiments. Total RNA was used for microarray analysis as well as for reverse 
transcription quantitative polymerase chain reaction (QRT-PCR). 
6.14. Microarrays and probes 
Construction and use of microarrays were performed as described [50, 51]. Briefly, 3200 
amplified cDNA inserts from different mouse cDNA libraries were amplified with vector-
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specific primers, analyzed with agarose gel electrophoresis, and purified with Millipore PCR 
purification plates. Purified PCR products were reconstituted in 50% dimethylsulfoxide/water 
and arrayed in duplicate on FMB cDNA slides (Full Moon Biosystems, Sunnyvale, CA, USA) 
using a Micro-Grid Total Array System spotter (BioRobotics, Cambridge, UK) with 16 pins in a 
4x4 grid format. After printing, DNA was UV crosslinked to the slides with 700 mJ energy 
(Stratalinker, Stratagene). Microarray probes were generated by a modified version of a linear 
amplification technique described before [46, 48]. Briefly, 2 pg total RNA from each pooled 
sample was amplified. Three pg of amplified RNA was labeled with both Cy5 and Cy3 
fluorescent dyes (dye-swap experiments) during RT with RNase H (-) point mutant M-MLV 
reverse transcriptase (Fermentas, Vilnius, Lithuania) and random nonamers. After RT, RNA was 
alkali hydrolyzed and labeled cDNA was purified with NucleoSpin PCR purification kit 
(Macherey-Nagel) according to the manufacturer's instructions. Probes generated from the 
control and treated samples were mixed, reconstituted in 16 pi hybridization buffer (50% 
formamide, 5xsaline sodium citrate (SSC), 0.1% SDS, 100 pg/ml salmon sperm DNA) and 
applied onto the array after denaturation by heating for 1 min at 90°C. Prior to hybridization, the 
slides were blocked in 1 xSSC, 0.2% SDS, 1% bovine serum albumin for 30 min at 45°C, rinsed 
in water and dried. The slide was covered by a 22 mmx22 mm coverslip, and sealed with DPX 
Mountant (Fluka, Buchs, Switzerland) in order to prevent evaporation. Slides were incubated at 
42°C for 20 h in a humid hybridization chamber. After hybridization the mountant was removed 
and the arrays were washed by submersion and agitation for 10 min in lxSSC with 0.1% SDS, 
for 10 min in O.lxSSC with 0.1% SDS and for 10 min in O.lxSSC at room temperature, then 
rinsed briefly in water and dried. Each array was scanned under a green laser (543 nm for Cy3 
labeling) or a red laser (633 nm for Cy5 labeling) using a ScanArray Lite (GSI Lumonics, 
Billerica, MA, USA) scanning confocal fluorescent scanner with 10 pm resolution (laser power: 
85% for Cy5 and 90% for Cy3, gain: 75% for Cy5 and 70% for Cy3) [49]. Scanned output files 
were analyzed using the GenePix Pro 3.0 software (Axon Instruments, Foster City, CA, USA). 
Each spot was defined by automatic positioning of a grid of circles over the image. The average 
and median pixel intensity ratios calculated from both channels and the local background of each 
spot were determined. An average expression ratio (MeaR, denotes the average of local 
background corrected pixel intensity ratios) was determined for each spot. Normalization was 
performed by the global Lowess method [53]. Those data were flagged and excluded where the 
replicate spots from a different site of the same array or results from the replicate experiments 
were significantly different. Data analysis was done by the significance analysis of microarrays 
method [54] and visualization of scatter images was performed with the Microsoft EXCEL 
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software. The cholesterol-regulated genes were determined by calculating the average fold 
change between heart samples from untreated and cholesterol-fed animals. From two biological 
replicates and two hybridizations altogether four data points were gathered from each gene. 
Genes for which the average change (increase or decrease) of the four data points was at least 
1.9-fold were considered genes regulated by cholesterol diet. 
6.15. Real-time QRT-PCR 
Confirmatory real-time QRT-PCR was performed on a RotorGene 2000 instrument (Corbett 
Research, Sydney, Australia) with gene-specific primers and SYBR Green protocol to confirm 
the gene expression changes observed by DNA microarrays as described [49]. In brief, 10 pg of 
total RNA from each pool was reverse transcribed in the presence of oligo(dT) primer in a total 
volume of 20 pi. After dilution of the mix with 80 pi of water, 2 pi of this mix was used as 
template in the QRT-PCR. Reactions were performed in a total volume of 20 pi (8 pmol/each 
forward and reverse primer, 1 xBio-Rad SYBR Green buffer, Bio-Rad, Hungary) with the 
following protocol: 10 min denaturation at 95°C, and 45 cycles of 25 sec denaturation at 95°C, 
25 sec annealing at 59°C, and 25 sec extension at 72°C. Fluorescent signals were gathered after 
each extension step at 72°C. Curves were analyzed by the RotorGene software using dynamic 
tube and slope correction methods ignoring data from cycles close to baseline. Relative 
expression ratios were normalized to L-actin and calculated with the Pfaffl method [55]. Primers 
were designed using the ArrayExpress software (Applied Biosystems). All the PCRs were 
performed four times in separate runs. 
6.16. Statistical analysis 
Results were expressed as mean±SEM and analyzed by SigmaStat software (Jandel 
Scientific, Costa Madre, CA) as appropriate. Student's T-test, or one way analysis of variance 
(ANOVA) followed by Tukey post-hoc test was used to evaluate differences between groups, as 
appropriate. Differences were considered significant at p<0.05. 
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7. RESULTS 
7.1. Study 1 
7.1.1. Cardiac NO content 
After an 9-week cholesterol-enriched diet, myocardial NO level was significantly decreased 
in cholesterol-fed animals when compared to normal rats as assessed by electron spin 
spectroscopy after in vivo spin trapping. To test if the decreased NO level in cholesterol-fed rats 
is due to inhibition of the mevalonate pathway, cholesterol-fed rats were treated with farnesol, a 
major metabolite of the mevalonate pathway. Farnesol treatment did not influence the attenuated 
NO level in the cholesterol-fed group or the basal NO level in the normal group. To further test 
if a direct inhibition of HMG-CoA reductase changes NO content, normal and cholesterol-fed 
rats were treated with lovastatin. Lovastatin failed to change cardiac NO when compared to 
nontreated normal or cholesterol-fed groups, respectively (Fig. 3). 
Figure 3. Cardiac NO level measured by 
electron spin resonance spectroscopy in rat 
hearts. 
Rats were fed 2% cholesterol-enriched 
(Choi) or normal diet (Cont) for 9 weeks. 
Normal and cholesterol-fed animals were 
treated with farnesol (Far; Chol+Far), a 
major metabolite of the mevalonate 
pathway (2.2 mgxkg"1 i p ) , or with the 
HMG-CoA reductase inhibitor lovastatin 
(Lov; Chol+Lov, 3x5 mgxkg"1 per os for 3 
days, n=5-6 in each group). Data are mean 
± SEM. *p<0.05 vs. controls. 
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7.1.2. Cardiac NOS activities and eNOS protein levels 
To test if changes in cardiac NO level is due to different rate of NO synthesis, NOS 
• 9 i 
activities and NOS protein contents were assayed. Cardiac Ca -dependent NOS activity was not 
influenced by cholesterol-enriched diet when compared to normal controls. Neither farnesol, nor 
lovastatin influenced cardiac NOS activities (Fig. 4A). Similarly to NOS activities, cardiac 
eNOS protein content was not influenced by the different treatments (Fig. 4B). As cardiac 
calcium-independent iNOS activity was below the detection limit in all groups, cardiac iNOS 
protein content was not measured. 
•j SZKT-E-I-
13. 
t } 
y 
21 
Figure 4. Cardiac eNOS activity assessed by a 
14C-citrulline assay (A) and cardiac eNOS protein 
content measured by western blotting (B). 
Rats were fed 2% cholesterol-enriched (Choi) or 
normal diet (Cont) for 9 weeks. Normal and 
cholesterol-fed animals were treated with farnesol 
(Far; Chol+Far), a major metabolite of the 
mevalonate pathway (2.2 mgxkg"1 i.p.), or with 
the HMG-CoA reductase inhibitor lovastatin (Lov; 
Col+Lov, 3x5 mgxkg"1 per os for 3 days, n=5-6 in 
each group). Data are mean ± SEM. 
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7.1.3. Cardiac superoxide production 
To investigate if cardiac NO level is decreased in cholesterol-fed animals due to increased 
free radical formation, we measured superoxide-anion production in hearts of normal and 
cholesterol-fed animals by lucigenin-enhanced chemiluminescence assay. Cholesterol-enriched 
diet significantly increased superoxide production (control: 146.9±9.4, hyperlipidemic: 
366.4±35.0 cpmxmg"1 wet weight, p<0.05, n=6 and 7). 
7.2. Study 2 
7.2.1. Effect of preconditioning on infarct size and LDH release in control and 
cholesterol-fed groups 
To assess the cardioprotective effect of preconditioning, we measured infarct size after test 
ischemia/reperfusion. In control hearts, preceding preconditioning significantly decreased infarct 
size as compared to nonpreconditioned hearts. In hearts of cholesterol-fed animals, 
preconditioning failed to significantly decrease infarct size (Fig. 5A). 
LDH release was measured in coronary perfusate to detect ischemic injury. Thirty min test 
ischemia followed by 5 min reperfusion resulted in a significant LDH release in the 
nonpreconditioned control group. In the preconditioned control group, LDH release was 
significantly attenuated. In the cholesterol-fed group, preconditioning failed to decrease LDH 
release (Fig. 5B). 
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Figure 5. Infarct size and LDH release. 
Preconditioning significantly decreased infarct 
size (panel A) and lactate dehydrogenase 
release (LDH, panel B) in control chow-fed 
rats (Control Pre) as compared to 
nonpreconditioned controls (Control). 
Preconditioning did not significantly decrease 
infarct size and LDH release in 
hyperlipidemic rats (Choi and Choi Pre). n=6-
8; *p<0.05 vs. Control. 
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7.2.2. Effect of preconditioning on myocardial MMP-2 activation and its release into 
the perfusate in control and cholesterol-fed groups 
To assess myocardial MMP-2 activation and release, zymographic analysis was performed 
in cardiac tissue and coronary perfusate samples (pre and post ischemia/reperfusion, see Fig. 2). 
In the control chow-fed nonpreconditioned and the cholesterol-fed nonpreconditioned groups, a 
loss of cardiac 72 and 62 kDa MMP-2 activities was noted following ischemia/reperfusion (Fig. 
6A). This loss was accompanied by an increase in 72 and 62 kDa activities in the coronary 
perfusate (Fig. 6B). In the control chow-fed group, preconditioning attenuated the release of 72 
and 62 kDa MMP-2 by 17.6±3.4% (p<0.05) and 21.9±7.9% (p<0.05), respectively, as compared 
to the control nonpreconditioned group. In the cholesterol-fed group, however, preconditioning 
failed to inhibit the ischemia/reperfusion-induced release of cardiac MMP-2 activity when 
compared to the cholesterol-fed nonpreconditioned group (Fig. 6B). 
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Figure 6. Cardiac and perfusate MMP 
activities. 
Panel A: Thirty min ischemia induced a 
loss of myocardial MMP-2 (both 72 and 
62 kDa forms), in normal (Control) and 
cholesterol-fed (Choi) groups. In control 
hearts, ischemia-induced loss of cardiac 
MMP-2 was reduced by preconditioning 
as compared to nonpreconditioned 
control group (Control vs. Control Pre). 
Preconditioning in cholesterol-fed rats 
failed to inhibit the ischemia-induced 
loss of MMP-2 activity (Choi vs. Choi 
Pre). n=6 in each group; *, # p<0.05 vs. 
Control-after ischemia. 
Panel B: Thirty min ischemia increased 
myocardial release of MMP-2 into the 
perfusate (Control), which was 
attenuated by preconditioning in hearts 
from control chow-fed rats (Control 
Pre). However, in the hyperlipidemic 
group preconditioning failed to attenuate 
myocardial MMP-2 release into the 
coronary perfusate (Choi vs. Choi Pre). 
n=6 in each group; *p<0.05 vs. Control-
after ischemia. 
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7.2.3. TIMP-2 and 4 western blot 
To measure cardiac protein level of endogenous MMP inhibitors, we performed TIMP-2 and 
TIMP-4 western blots from cardiac tissue samples collected 5 min after test ischemia. Western 
blots show that neither cholesterol diet nor preconditioning influenced TIMP-2 or TIMP-4 
protein level after 30 min test ischemia followed by 5 min reperfusion in the isolated rat heart 
(Fig. 7A-B). 
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Figure 7. TIMP-2 and TIMP-4 western blots. 
Representative western blots show 27 and 21 
kDa bands for TIMP-2, as well as 29 and 23 
kDa bands for TIMP-4, known as glycosylated 
and unglycosylated proteins, respectively. 
Neither hyperlipidemia, nor test ischemia, or 
preconditioning significantly affected cardiac 
total TIMP-2 (A), or total TIMP-4 (B) protein 
level as assessed by western blots. n=6 in each 
group. 
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7.2.4. Effect of ilomastat on infarct size and LDH-release 
To prove the causative relationship between MMP inhibition and limitation of infarct size, 
we mimicked the MMP inhibitory effect of preconditioning by a pharmacological inhibition of 
MMP-2 activity by approximately 20%, as observed in preconditioned control hearts. Therefore, 
first we determined the concentration of ilomastat that inhibits cardiac MMP-2 by approximately 
17-22% in vitro (Fig. 8). We found that ilomastat inhibited myocardial MMP-2 activity by 
3.0±0.8% at 0.1 pM and 19.1±1.4% at 0.25 pM. Therefore, we chose 0.25 pM and 0.1 pM for 
further heart perfusion studies. After test ischemia/reperfusion 0.1 pM ilomastat failed to 
significantly decrease infarct size and LDH release in hearts of both control and cholesterol-fed 
animals, however 0.25 pM ilomastat significantly decreased infarct size and LDH release both in 
control and cholesterol-fed group also (Fig. 9A-D). Ilomastat did not influence heart rate and 
coronary flow in either control or cholesterol-fed group (data not shown). These results 
demonstrate that 0.25 pM ilomastat protected hearts against ischemic injury not only in hearts 
from control chow-fed rats, but also in those from cholesterol-fed animals. 
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Figure 8. Effect of ilomastat on MMP-2 activity 
in vitro. 
MMP-2 activity in nontreated heart tissue 
homogenate was assessed by zymography in the 
presence of 0, 0.01, 0.1, 0.25, 0.5, 1 and 10 pM 
ilomastat for 3 hours in the incubation buffer. 
n=3 in each group. 
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Figure 9. Effects of ilomastat on infarct size and LDH release in control and cholesterol-fed 
group. 
Ilomastat (0.1 pM and 0.25 pM) dose-dependently decreased infarct size and LDH release both 
in control (panel A and C) and cholesterol-fed rats (panel B and D). n=5-8 in each group; 
*p<0.05 vs. Control or Choi. 
7.2.5. Effect of hyperlipidemia on cardiac nitrotyrosine level 
In order to investigate whether hyperlipidemia influences cardiac formation of ONOO", we 
have measured cardiac nitrotyrosine level and found that hyperlipidemia significantly increased 
nitrotyrosine formation in the heart, as compared to controls (Fig. 10). 
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Figure 10. Effects of hyperlipidemia on 
cardiac nitrotyrosine. 
Hyperlipidemia enhanced baseline cardiac 
nitrotyrosine formation as compared to 
controls (n=4 in each group; */?<0.05 vs. 
Control). 
7.3. Study 3 
7.3.1. Effect of hyperlipidemia on cardiac functions 
Similarly to our previous results [10, 29], left ventricular end diastolic pressure was 
significantly increased in the hyperlipidemic group showing a mechanical dysfunction of the 
heart (Table 1). Other hemodynamic parameters including coronary flow were not changed by 
hyperlipidemia (Table 1) and no lactate dehydrogenase release was detected (data not shown) 
indicating that hyperlipidemia did not result in restriction of coronary circulation and 
development of myocardial ischemia. Therefore, gene expression changes observed in this study 
can be attributed to a direct effect of chronic hyperlipidemia on the myocardium. 
HR CF AF LVDP +dP/dtmax -dP/dtmax LVEDP 
Control 2 7 3 ± 6 2 3 . 0 ± 0 . 5 4 4 . 4 ± 2 . 0 1 8 . 5 ± 0 . 4 8 4 4 ± 4 6 4 5 6 1 3 1 0 . 5 1 1 0 . 0 5 
Choi 2 7 1 ± 8 2 1 . 9 ± 0 . 5 4 5 . 1 + 1 . 3 1 8 . 9 + 0 . 5 9 3 5 ± 5 0 4 7 8 1 4 3 0 . 8 7 1 0 . 0 5 * 
Table 1. Cardiac functional parameters in control and cholesterol-fed groups 
Heart rate (HR, beatsxmin"'); Coronary flow (CF, mlxmin"1); Aortic flow (AF, mlxmin"1); Left 
ventricular developed pressure (LVDP, kPa); Left ventricular end-diastolic pressure (LVEDP, 
kPa); +dP/dtmax (kPaxs"1); -dP/dtmax (kPaxs"1). Values are means ± SEM (n=8 in each group). 
*p<0.05 shows significant difference compared to control by Student's t-test. 
7.3.2. Effect of hyperlipidemia on cardiac gene expression 
Relative gene expression changes in rat hearts in response to cholesterol diet-induced 
hyperlipidemia were compared to the expression profiles of rats on a normal diet. Changes of 
3200 genes were followed by mouse-specific cDNA microarrays. Among the 3200 genes 
examined in the present study an average of 1324 showed significant intensity and 4.0% (51 
genes) showed altered expression: 26 genes exhibited significant up-regulation (Table 2A) and 
25 were down-regulated (Table 2B) after 9 weeks of high-cholesterol diet. Out of the 51 genes, 
43 genes of known function and eight expressed sequence tags (ESTs) or hypothetical protein 
140 
120 • <D C 
O S 1 0 0 
o Q. 
'E b) 
o E 
. 2 CD -o S 
re 
O 
80 
60 
40 
20 
Control Choi 
genes with unknown function were detected. The gene expression changes ranged from -4.4-fold 
to +5.5- fold (Table 2). 
Function Gene Product Acc. no. 
Microarray 
(average-
fold) 
SD 
Structural proteins Cofilin/destrin 
(actin depolymerizing factor) 
W17549 3.15 0.21 
Calsarcin-1, myozenin-like 2 XM 215692 2.35 0.52 
Procollagen, type III, alpha 1 W89883 2.14 0.50 
Regulatory proteins Protein phosphatase 1, regulatory 
subunit 9A 
AA087542 4.80 1.52 
Transcription repressor p66 XM 227388 3.38 0.80 
Sim. to developmentally reg. prot AA259357 3.52 0.39 
Pleiotropic regulator 1 AA286018 2.77 0.20 
Glycogen synthase kinase-3 NM 032080 1.95 0.04 
Protein kinase C inhibitor, iota NM 022192 1.90 0.03 
Adhesion molecules, 
membrane proteins 
p i20 catenin isoform 4B AW545658 5.48 1.84 
SH3-containing protein SH3P4 W34672 5.11 0.74 
Clara cell phospholipid-binding prot. W36838 4.51 0.71 
NIPSNAP2 protein W15931 3.00 0.34 
Tensin U26310 1.97 0.19 
Stress proteins Glutathione S-transferase AA231621 3.26 0.20 
Metallothionein II H32024 1.97 0.06 
Heat shock Protein, Hsp86 AW536140 1.95 0.14 
Others Engulfment and cell motility 2 AA087542 4.80 0.34 
Disintegrin, metalloprotease domain 
10 
AA267983 3.21 0.32 
Mad-related protein Smad7 AA068440 2.70 0.28 
Horn, to ribosomal RNA processing 4 NM 144886 2.58 0.20 
Synaptic vesicle protein 2B AF372834 1.96 0.09 
Hypothetical Hypothetical protein AA245492 4.57 0.56 
KIAA0719 protein AW545304 3.70 0.93 
Hypothetical XM 220393 2.27 0.41 
H. sapiens HSPC137 AW545388 1.92 0.18 
Table 2A. Up-regulated genes due to high-cholesterol diet-induced hyperlipidemia in rat hearts 
SD - standard deviation 
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Function Gene Product Acc. no. 
Microarray 
(average-
fold) 
SD 
Energy metabolism Sarcomeric mit. creatine kinase XM 226693 -3.58 0.81 
Enolase 3, beta W11965 -3.15 0.27 
NADH-ubiquinone oxidored. W83085 -2.59 0.26 
Muscle form glycogen 
phosphorylase 
W16286 -2.34 0.26 
ND5 resp. NADH dehydrog. S46798 -2.08 0.08 
ATP synthase subunit c D13123 -2.07 0.09 
Ion channels, 
Receptors 
Fibronectin receptor beta-chain AW544628 -3.29 0.53 
Sodium/potassium ATPase beta AW544502 -2.02 0.34 
Chloride intracellular channel 4 NM 031818 -2.00 0.12 
Intracell. chloride channel pr. AW539790 -1.95 0.20 
Protein degradation, 
Folding (chaperons) 
Proteasome component C9 AA277958 -3.60 0.92 
Ubiquitin-like protein FUBI AA239437 -3.47 0.57 
105-kDa heat shock protein AW544862 -2.71 0.32 
Calreticulin AW545345 -2.26 0.35 
Chaperonin subunit 5, epsilon AA955792 -2.00 0.08 
Cholesterol synthesis, 
transprot 
START domain containing 7 W36450 -3.61 0.43 
Farnesyltransferase beta subunit AA259357 -2.05 0.09 
CEA-related cell adhesion mol. 9 AW545543 -1.98 0.12 
Others Fibroblast inducible secreted pr. W36541 -2.68 0.02 
Basigin AW544934 -2.26 0.43 
CD81 antigen NM 013087 -2.09 0.35 
Hypothetical Hypothetical protein AA403436 -4.45 0.51 
mKIAA0475 protein AA274981 -2.33 0.99 
EST W44032 -2.33 0.21 
EST AA068436 -2.17 0.37 
Table 2B. Down-regulated genes due to high-cholesterol diet-induced hyperlipidemia in rat 
hearts. SD - standard deviation 
7.3.3. Confirmation of microarray results by QRT-PCR 
In order to confirm the differential expression of genes revealed by microarray analysis of 
rat hearts after cholesterol diet, several genes were analyzed by RT-PCR. We have selected 12 
genes differentially expressed in hearts from cholesterol-fed animals for real-time RT-PCR 
analysis (Table 3). Results for 11 genes were in agreement with the microarray data, while in 
case of glycogen synthase kinase 3K gene, the moderate alteration in its expression (a 
statistically borderline case) could not be confirmed. Genes encoding procollagen type III Kl , 
synaptic vesicle protein 2B, tensin, heat shock protein Hsp86 and metallothionein II had very 
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significant rises in transcription rate. In all these cases, more pronounced induction could be 
detected by QRT-PCR than with the microarray technique. A higher degree of change was also 
observed in the repression of CD81 antigen. Gene expression changes obtained by QRT-PCR for 
genes encoding ATP synthase subunit c, chloride intracellular channel 4, protein kinase C 
inhibitor S, ND5 respiratory NADH dehydrogenase, and chaperonin subunit 5 0 were repressed 
and values were very similar to those obtained in the microarray measurements. 
Gene Product 
Accession 
Number 
Microarray 
(average-
fold) 
Real-time 
PCR 
(average-fold) 
Average 
Ct 
values 
Confirmed 
by real-
time PCR 
Procollagen, type III, alpha 1 W89883 2.14 4.15 15.24 Yes 
Synaptic vesicle protein 2B AF372834 1.96 3.86 14.32 Yes 
Tensin U26310 1.97 2.76 16.40 Yes 
Heat shock protein, Hsp86 NM 175761 1.95 2.45 16.43 Yes 
Protein kinase C inhibitor, 
iota 
NM_022192 1.90 1.74 14.95 Yes 
Glycogen synthase 
kinase-3 alpha 
NM_032080 1.95 -1.60 12.65 No 
Metallothionein II H32024 1.97 2.46 16.74 Yes 
ATP synthase subunit c D13123 -2.07 -1.92 10.52 Yes 
Chloride intracellular 
channel 4 
NM_031818 -2.00 -1.74 16.14 Yes 
ND5 resp. NADH dehydrog. S46798 -2.08 -2.16 8.56 Yes 
Chaperonin subunit 5, epsilon AA955792 -2.00 -2.20 16.98 Yes 
CD81 antigen NM 013087 -2.09 -3.44 14.35 Yes 
Table 3. Confirmation of gene expression changes due to high cholesterol diet-induced 
hyperlipidemia by real-time PCR in rat hearts. Ct - threshold cycle. 
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8. DISCUSSION 
8.1. New findings 
1. Hyperlipidemia-induced decrease in cardiac NO level is not associated with 
changes in cardiac NOS activities and NOS protein content. 
2. HMG-CoA reductase inhibitor lovastatin, or farnesol, a major metabolite of the 
mevalonate pathway, fail to restore cardiac NO level in hyperlipidemic rats. 
3. Neither farnesol, nor lovastatin affects cardiac NO level, NOS activities, and 
NOS protein in normal rats. 
4. Cardiac superoxide generation is enhanced in hyperlipidemic rats. 
5. Hyperlipidemia blocks the inhibition of ischemia-induced activation and release 
of myocardial MMP-2 brought about by preconditioning and therefore 
attenuates the infarct size-limiting effect of preconditioning. 
6. Preconditioning-induced inhibition of ischemia-induced MMP-2 activation and 
release is not mediated by a change in cardiac TIMP-2 or 4 levels. 
7. Pharmacological inhibition of MMPs markedly reduces infarct size in both 
control and hyperlipidemic rats. 
8. Nine weeks of cholesterol-enriched diet up-regulate cardiac expression of 26, 
and down-regulate that of 25 genes out of the examined 3200. 
8.2. Changes in NO bioavailability by modulation of the mevalonate 
pathway 
A number of evidences suggest that HMG-CoA reductase inhibitors (statins) affect vascular 
NO production in different experimental models. Inhibition of HMG-CoA reductase by statins 
blocks hypoxia-mediated down-regulation of eNOS and increases eNOS mRNA level in the 
mouse aorta [26, 56] and in hypercholesterolemic rabbits [57]. Endres et al. [58] found that 
simvastatin increased the activity of calcium-dependent NOS in the mouse aorta by 2- to 3-fold. 
Increased NO level has been reported in cultured bovine aortic endothelial cells after simvastatin 
treatment [59]. Although these findings suggest the role of the mevalonate pathway in the 
regulation of vascular NO production, the exact mechanisms remained unknown. 
In contrast to the aforementioned findings in vascular tissue, we have found here that in the 
heart tissue, neither hyperlipidemia nor inhibition of HMG-CoA reductase by lovastatin affected 
NOS activities and NOS protein content. This may show that the regulation of NOS activities 
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and NOS protein synthesis is not affected significantly by the mevalonate pathway in the heart 
tissue. 
It is well known that high cholesterol level influences NO-cGMP signaling pathway. Lefer 
and Ma observed a reduced NO release from rabbit aorta in hypercholesterolemia [25]. 
Deliconstantinos et al. showed that incorporation of high concentration of cholesterol into 
endothelial cell membranes caused a down-regulation of NO synthesis in cultured bovine aortic 
endothelial cells [60]. Feron et al. found that in cultured bovine aortic endothelial cells, 
experimental hypercholesterolemia decreased NO production but did not affect eNOS protein 
content [61]. Further studies in this model showed that hypercholesterolemia-induced 
deterioration of NO production, measured in a single cell by NO selective electrode, was due to 
increased production of caveolin-1 [62]. In contrast to these findings, increased eNOS level and 
NO production were found in cholesterol treated cultured bovine aortic endothelial cells [63]. 
We have found in the present study that cholesterol diet-induced hyperlipidemia although 
decreases NO level, but it does not change NOS activity and NOS protein content in the rat 
heart. This shows that decreased cardiac NO level is not due to impaired NO synthesis, however, 
it suggests that breakdown of cardiac NO is increased due to hyperlipidemia. The mechanism of 
decreased cardiac NO level in hyperlipidemia remains unknown, however, it is well known that 
hyperlipidemia leads to increased production of ROS in the vasculature which leads to formation 
of ONOO" [64-69]. We have found here an increased superoxide production in hyperlipidemic 
hearts, so it is plausible to speculate that elevated ROS production is responsible for decreased 
NO level in hyperlipidemic myocardium. The source of increased superoxide formation in 
hyperlipidemic hearts has not been determined in the present studies. It has been previously 
shown that hypercholesterolemia leads to increased angiotensin II levels and angiotensin 
receptor subtype 1 expression, which up-regulates NADPH oxidase activity, a major source of 
superoxide in the vasculature [70, 71]. Therefore, it is plausible to speculate that increased 
NADPH oxidase activity due to hyperlipidemia is a major source of increased superoxide 
production in hyperlipidemic hearts. 
8.3. Loss of preconditioning in hyperlipidemia 
We have shown here that the protective effect of preconditioning was lost in hearts from 
cholesterol-fed rats, as preconditioning failed to reduce infarct size and LDH release in the 
hyperlipidemic group. This is in agreement with Ueda et al., who found that the infarct size 
limiting effect of preconditioning was significantly attenuated in rabbits fed 1% cholesterol-
enriched diet for 16 weeks [72]. Moreover, Juhasz et al. found a significant increase in infarct 
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size in preconditioned hyperlipidemic rabbits compared to nonpreconditioned ischemic control 
[73]. In contrast to these studies, in apolipoprotein E/low density lipoprotein receptor double 
knockout mice fed a 0.15% cholesterol- and 21% fat-enriched diet for 8 months [74] or in 
rabbits fed a cholesterol-enriched diet for 8 weeks [75], or cholesterol and coconut-oil rich chow 
for 4 weeks [76], the infarct size limiting effect of preconditioning was preserved. The 
discrepancies can be attributed to substantial differences in experimental hyperlipidemia 
(species, duration and composition of diet) leading to differences in the severity of coronary 
atherosclerosis. To exclude the effect of coronary sclerosis-induced disturbances of coronary 
perfusion we used hearts of male Wistar rats to study the direct cardiac effect of dietary 
cholesterol, since this species shows a moderate increase in serum cholesterol level due to a 
cholesterol-enriched diet without substantial development of atherosclerosis. Most of the studies 
to date including our present study show that the cardioprotective effect of preconditioning is 
reduced in hyperlipidemic animals and in humans as well (see for reviews) [8, 77,78]. 
Mechanisms by which hyperlipidemia affects preconditioning are not exactly known. A few 
studies demonstrated structural and functional alterations in the myocardium due to 
hypercholesterolemia [79, 80]. Ecto-5'-nucleotidase activity [72], inhibition of the mevalonate 
pathway [41], as well as enhanced apoptotic cell death [35] have been shown to contribute to the 
increased ischemia-reperfusion injury and to the loss of preconditioning in hyperlipidemic 
animal models. We have previously reported that diminished NO bioavailability plays an 
important role in the loss of pacing-induced preconditioning in hyperlipidemia [10]. 
Furthermore, we have shown that hyperlipidemia leads to increased formation of ONOO" in the 
heart [29]. As it was shown that ONOO" oxidatively activates MMPs [30], and that MMPs, as 
downstream targets of ONOO", contribute to ischemia-induced cardiac injury [34], here we 
hypothesized that altered activation of MMP-2 and its release into the perfusate might contribute 
to preconditioning-induced cardioprotection and to the loss of preconditioning in 
hyperlipidemia. 
8.4. Role of MMPs in preconditioning 
To test this hypothesis, in the present study we measured MMP-2 activity in the heart and in 
the coronary perfusate, as well as its physiological inhibitors TIMP-2 and TIMP-4 proteins in 
cardiac tissue. The most abundant MMP in the rat heart is MMP-2. MMP-2 appears as both 72 
kDa (oxidatively activated pro-MMP-2) and 62 kDa (proteolytically activated MMP-2) 
gelatinolytic bands. A 75 kDa glycosylated MMP-2 activity has also been identified in rat hearts 
(personal communication, Chris Overall, University of British Columbia). The 75 kDa activity 
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appeared only intermittently, therefore, we excluded it from data analysis. As previously 
reported [34, 35], MMP-9 (92 kDa and 84 kDa) was not detectable by zymography in cardiac 
tissue or perfusate samples in our present studies, since MMP-9 is predominantly synthesized by 
leucocytes. Here we have shown that activation of MMP-2 in the heart as a result of ischemia-
reperfusion injury results in its enhanced release into the perfusate during reperfusion which is 
accompanied by a decrease in its activity in the myocardium. Our data suggest that ischemia-
induced release of cardiac MMP-2 is not a passive necrosis-related mechanism, but an active 
process, since we have found increased MMP-2 normalized to total protein release. Our previous 
studies with MMP inhibitors also showed an active contribution of MMP-2 release and 
activation to cardiac dysfunction upon reperfusion [34]. While cardiac MMP-2 was released 
immediately after test ischemia into the perfusate, the level of its inhibitors, TIMP-2 and TIMP-
4, was not changed in the heart in the present study. This shows that MMP-2 is released without 
its main inhibitors, the TIMPs, therefore it might be activated. We have found in the present 
study that preconditioning failed to attenuate ischemia-induced activation and release of MMP-2 
in hearts of hyperlipidemic rats, however, the cardiac protein level of the most abundant 
endogenous MMP-2 inhibitors, TIMP-2 or TIMP-4, were unaffected in either group. This shows 
that preconditioning inhibits ischemia/reperfusion-induced activation and release of MMP-2 
independently of TIMP-2 and TIMP-4 and that hyperlipidemia blocks the effect of 
preconditioning on MMP-2 activation and release. 
The mechanism by which hyperlipidemia interferes with MMP activation and release during 
preconditioning is unknown. Enhanced MMP-1 activity was found in the plasma and in aortic 
rings from hyperlipidemic pigs [81], which was reduced by oral administration of antioxidant 
vitamin C and E. This suggests that hyperlipidemia may induce oxidative activation of MMPs. 
Pro-MMP-2 may be activated not only through proteolytic cleavage yielding 62 kDa MMP-2, 
but also through oxidant-induced conformational change. Indeed, the powerful oxidant ONOO" 
was shown to directly activate MMPs by S-glutathiolation of a cystein residue in the 
autoinhibitory pro-peptide domain, allowing the conformational change which results in a fully 
active 72 kDa pro-MMP-2 [30, 82]. Moreover, we have previously demonstrated that infusion of 
ONOO" into isolated rat hearts induces myocardial MMP-2 activation and its release into 
coronary perfusate, followed by a subsequent loss in cardiac contractile function, the latter 
blocked by treating the heart with a MMP inhibitor [35]. Furthermore, we have also shown that 
preconditioning attenuates the activation and release of myocardial MMP-2, thereby protecting 
the heart from ischemic injury. Thus, it is plausible to speculate that the loss of preconditioning-
induced inhibition of MMP-2 activation and release, which is independent of TIMPs but might 
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be related to increased oxidative stress, is involved in the loss of cardioprotective effects of 
preconditioning in hyperlipidemia. Indeed, similarly to our previous studies, here we have 
demonstrated an increased baseline ONOO" formation in the hyperlipidemic heart, however, it 
did not result in increased baseline MMP activation. This suggests that the link between 
oxidative stress and MMP activation is rather complex in the heart. Further studies are necessary 
to follow changes in formation of reactive oxygen species and MMP activation during 
preconditioning in both normal and hyperlipidemic heart to reveal the mechanism by which 
hyperlipidemia interferes with preconditioning-induced MMP activation and release. 
To test if the inhibition of MMP-2 activation and release is a key mechanism in the infarct 
size limiting effect of preconditioning, first we selected a concentration of the MMP inhibitor 
ilomastat that shows a similar extent of MMP-2 inhibition to that of preconditioning, i.e. 18%. 
Then we tested if 18% inhibition of MMP-2 by ilomastat reduces infarct size in normal and 
hyperlipidemic rats. We found here that acute, approximately 18% inhibition of MMPs by 0.25 
pM ilomastat decreased infarct size similarly to the effect of preconditioning in normal hearts. 
This strongly suggests that inhibition of MMPs is an effector mechanism in the cardioprotective 
mechanism of preconditioning. Moreover, we have found that ilomastat reduced infarct size in 
hyperlipidemic rat hearts as well. These findings show that the lack of MMP inhibition 
contributes to the loss of preconditioning in hyperlipidemia, as pharmacological inhibition of 
MMP attenuates ischemia/reperfusion injury even in hearts from rats fed a cholesterol-enriched 
diet. 
8.5. Cardiac expression of gene families down-regulated by hyperlipidemia 
We have found that hyperlipidemia significantly affected cardiac energy metabolism and the 
ATP generating machinery at the level of gene expression, as sarcomeric mitochondrial creatine 
kinase, enolase 3L, ND5 respiratory NADH dehydrogenase, NADH-ubiquinone oxidoreductase, 
muscle form glycogen phosphorylase, and ATP synthase subunit c were markedly down-
regulated as evidenced by microarray data and in the case of ATP synthase subunit c by RT-PCR 
results as well. These data are consistent with recent observations showing that 
hypercholesterolemia leads to an increase in mitochondrial damage in cardiovascular tissues 
[83]. Reduced energy metabolism and ATP synthesis may lead to functional deterioration of 
hyperlipidemic hearts as observed in our present and previous studies [10,29]. 
We have observed down-regulation of genes involved in cholesterol synthesis and transport 
in the heart after a high cholesterol diet. Steroidogenic acute regulatory protein-related lipid 
transfer (START) domains can bind sterol and perform critical functions in movine-thg-sterol 
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substrate to the mitochondrial inner membrane, and stimulate steroidogenesis [84]. The marked 
down-regulation of a START domain in the present study suggests that excess exogenous 
cholesterol inhibits intracellular cholesterol transport and steroidogenesis in the heart. The down-
regulation of farnesyltransferase L subunit can be attributed to inhibition of the mevalonate 
pathway (the pathway for cholesterol synthesis) due to excess exogenous cholesterol [24]. We 
have also observed a moderate repression of carcinoembryonic antigen-related cell adhesion 
molecule 9 (CEACAM9). Members of the CEACAM family of proteins play a role in the biliary 
cholesterol crystallization, promoting low-density protein-lipid complex [85], and serve as a 
potent angiogenic factor and a major effector of vascular endothelial growth factor [86]. These 
data suggest that dietary cholesterol reduces cardiac cholesterol synthesis and transport, and 
confirm our previous assumptions that high-cholesterol diet inhibits the mevalonate pathway 
thereby reducing protein prenylation and ubiquinone synthesis [41]. 
Genes encoding ion transport proteins and ion channels such as sodium/potassium ATPase 
L, chloride intracellular channel 4 (CLIC4), and intracellular chloride channel genes were also 
repressed. Decreased activity of sodium/potassium ATPase increases cardiac contractility, and 
may therefore be an adaptive response to attenuate hyperlipidemia-induced loss of cardiac 
function [87]. The role of the CLIC family of proteins is poorly understood, and no data are 
available on the role of CLIC in the heart; however, cellular volume control, cellular motility, 
and apoptosis have been suspected [88-90]. The possible role of CLIC in hyperlipidemia in the 
heart is an entirely new observation that needs further study. Another gene encoding a 
membrane-bound protein, fibronectin receptor L chain gene, was also markedly down-regulated. 
Integrins are heterodimeric receptors that couple the extracellular matrix to intracellular 
signaling pathways and the cytoskeleton. Integrins have been suggested to play a role in cardiac 
development and several cardiovascular disorders [91, 92]. Our present study is the first to 
suggest that down-regulation of fibronectin receptor plays a role in the cardiac effects of 
hyperlipidemia. 
8.6. Hyperlipidemia-induced cardiac overexpression of genes 
The most significantly up-regulated genes were membrane proteins, pi20 catenin isoform 
4B, SH3-containing protein SH3P4 (endophilin), Clara cell phospholipid binding protein, and 
NIPSNAP2 protein coding genes. The exact role of these proteins in the heart is not known. 
PI20 catenin affects cell-cell adhesion, as it controls internalization and degradation of classical 
cadherins in endothelial cells [93], and it is likely to have additional roles in the nucleus [94]. It 
is plausible to speculate that the expression changes of these membrane protein genes may be 
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partly the consequence of the possible alterations in membrane composition of the heart due to 
cholesterol diet-induced hyperlipidemia. 
Several regulatory protein genes were induced after cholesterol treatment: a protein kinase, a 
pleiotropic regulator, the regulatory subunit 9A of the protein phosphatase 1, and a 
transcriptional repressor. Among the regulatory protein coding genes, the protein kinase C 
inhibitor S gene was slightly induced, which was confirmed by QRT-PCR as well. Induction of 
this gene could have a dramatic effect on apoptosis of cardiomyocytes, as protein kinase C 
inhibitor S is the critical downstream target of Bcr-Abl, which mediates the anti-apoptotic effects 
of Bcr-Abl [95]. Moreover, Wang et al. have shown that diet-induced hypercholesterolemia in 
rabbits was associated with a markedly increased activation of caspase-3 and an increased 
myocardial Bcl-2/Bax ratio (markers of apoptosis) within the ischemic myocardium, showing 
the increased extent of cardiomyocyte apoptosis [96]. 
We have previously shown that transcription of hsp70 was significantly higher in hearts of 
rats fed a 2% cholesterol-enriched diet compared to normal controls, although the HSP70 protein 
level was not different [13]. We have also shown that hyperlipidemia inhibits expression of 
cardiac Hsp70 in response to heat stress and ischemia [13]. Here, we have detected extensive 
changes in the expression of stress proteins due to hyperlipidemia. The induction of heat stress 
proteins is well known in response to myocardial, renal, and cerebral ischemia [97-99], but this 
is the first demonstration that hsp86 and the antioxidants metallothionein II and glutathione S-
transferase can be induced by cholesterol diet. However, other stress proteins, such as 
chaperonin subunit 50, 105-kDa heat shock protein, calreticulin, and a ubiquitin-like protein 
were significantly down-regulated. Mechanisms that underlie the opposite regulation of these 
stress proteins due to high-cholesterol diet would be interesting to clarify, as still little is known 
about the function of these proteins in the heart [100,101]. 
Opposite changes in transcription of structural protein genes have been observed in the 
present study. Genes encoding a fibrogenic gene (fibroblast-inducible secreted protein) was 
down-regulated, while genes for cofilin/destrin (actin depolymerizing factor), calsarcin-1, 
myozenin-like 2, and procollagen III K1 were induced by high-cholesterol diet. Function of 
these proteins in the heart might be some remodeling process in response to hyperlipidemia. 
However, very little is known about the exact role of these genes in the heart. 
Activity of numerous genes with diverse function was also significantly altered in hearts of 
rats fed cholesterol-rich diet as shown in Table 2. For example, we have observed 
overexpression of Mad-related protein Smad7. Recent reports have implicated Smad7 as a 
crucial regulator of transforming growth factor L activity in human disease [102] and found that 
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Smad6 and Smad7 constitute a novel class of MAD-related proteins, termed vascular MADs, 
which are induced by fluid mechanical forces and can modulate gene expression in response to 
both humoral and biomechanical stimulation in vascular endothelium [103]. 
These findings show that various cellular mechanisms are involved in direct cardiac effect of 
hyperlipidemia induced by cholesterol-enriched diet, and emphasize that much more 
investigations should be carried out in order to thoroughly describe mechanisms underlying the 
hyperlipidemia in the heart. 
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9. CONCLUSIONS 
We demonstrated that modulation of the mevalonate pathway does not change 
bioavailability of NO in heart. Furthermore, hyperlipidemia-induced decrease in NO 
bioavailability in the heart is not dependent on the mevalonate pathway. Therefore, to restore 
NO level in the heart in hyperlipidemia, pharmacological manipulation of the mevalonate 
pathway does not seem to be a valid option. 
Our results show that hyperlipidemia blocks preconditioning-induced moderate inhibition of 
cardiac MMP-2 activation and release and therefore attenuates the infarct size limiting effect of 
preconditioning; preconditioning-induced inhibition of MMP-2 activation and release is 
independent of an effect of TIMP-2 or TIMP-4, and that pharmacological inhibition of MMPs by 
ilomastat reduces infarct size in both control and hyperlipidemic rats. These results strongly 
suggest that pharmacological inhibition of MMPs may be a powerful cardioprotective 
mechanism in acute ischemic challenge. 
Furthermore, we conclude that cholesterol-enriched diet-induced hyperlipidemia leads to 
significant changes in expression of several genes in rat hearts. As hyperlipidemia does not lead 
to coronary sclerosis and myocardial ischemia in our rat model, gene expression changes can be 
attributed to a direct effect of hyperlipidemia on the myocardium. The role of most of the genes 
we have found to be regulated by hyperlipidemia is not exactly known in the heart, therefore, our 
present findings open new directions in the research of the cardiac effects of hyperlipidemia. 
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